HistoSonics

HistoSonics develops histotripsy-based medical devices for the non-invasive destruction of targeted tumors. The company's flagship product, the Edison System, uses focused ultrasound to generate high-amplitude, short-duration pulses that create a 'bubble cloud' capable of mechanically destroying and liquefying liver tumors at a sub-cellular level — without incisions, radiation, or heat. The system received FDA clearance and is intended for the non-invasive mechanical destruction of liver tumors, including partial or complete destruction of unresectable tumors. HistoSonics originated from research at the University of Michigan and is advancing histotripsy into additional oncology indications, including pancreatic cancer through the GANNON trial.